1. Home
  2. TSBX vs XTKG Comparison

TSBX vs XTKG Comparison

Compare TSBX & XTKG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TSBX
    SELLHOLDBUYas of a day ago
  • XTKG
    SELLHOLDBUYas of a day ago
  • Stock Information
  • Founded
  • TSBX 2015
  • XTKG 1997
  • Country
  • TSBX United States
  • XTKG Singapore
  • Employees
  • TSBX N/A
  • XTKG N/A
  • Industry
  • TSBX
  • XTKG
  • Sector
  • TSBX
  • XTKG
  • Exchange
  • TSBX Nasdaq
  • XTKG NYSE
  • Market Cap
  • TSBX 8.4M
  • XTKG 8.5M
  • IPO Year
  • TSBX 2023
  • XTKG 2019
  • Fundamental
  • Price
  • TSBX $0.38
  • XTKG $1.11
  • Analyst Decision
  • TSBX Buy
  • XTKG
  • Analyst Count
  • TSBX 3
  • XTKG 0
  • Target Price
  • TSBX $4.75
  • XTKG N/A
  • AVG Volume (30 Days)
  • TSBX 130.4K
  • XTKG 163.0K
  • Earning Date
  • TSBX 05-12-2025
  • XTKG 05-21-2025
  • Dividend Yield
  • TSBX N/A
  • XTKG N/A
  • EPS Growth
  • TSBX N/A
  • XTKG N/A
  • EPS
  • TSBX N/A
  • XTKG N/A
  • Revenue
  • TSBX N/A
  • XTKG $15,234,138.00
  • Revenue This Year
  • TSBX N/A
  • XTKG N/A
  • Revenue Next Year
  • TSBX N/A
  • XTKG N/A
  • P/E Ratio
  • TSBX N/A
  • XTKG N/A
  • Revenue Growth
  • TSBX N/A
  • XTKG 51.59
  • 52 Week Low
  • TSBX $0.34
  • XTKG $0.08
  • 52 Week High
  • TSBX $3.88
  • XTKG $2.14
  • Technical
  • Relative Strength Index (RSI)
  • TSBX 44.53
  • XTKG 61.18
  • Support Level
  • TSBX $0.34
  • XTKG $1.07
  • Resistance Level
  • TSBX $0.42
  • XTKG $1.18
  • Average True Range (ATR)
  • TSBX 0.03
  • XTKG 0.11
  • MACD
  • TSBX -0.00
  • XTKG -0.00
  • Stochastic Oscillator
  • TSBX 42.70
  • XTKG 56.63

Stock Price Comparison Chart: TSBX vs XTKG

TSBX
XTKG
October2024AprilJulyOctober2025April0246810121416TSBX VS XTKG

About TSBX Turnstone Biologics Corp.

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

About XTKG X3 HOLDINGS CO LTD

X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries that operates across four business segments: digital technologies, renewable energy, Cryptomining Operations, and agriculture technologies.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use